(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.12%) $82.53
(0.69%) $2.04
(-0.58%) $2 344.10
(-1.19%) $27.33
(-0.17%) $959.90
(0.08%) $0.933
(0.11%) $10.99
(0.03%) $0.796
(0.01%) $93.31
-0.99% $ 30.06
Live Chart Being Loaded With Signals
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases...
Stats | |
---|---|
Volumen de hoy | 479.00 |
Volumen promedio | 1 524.00 |
Capitalización de mercado | 9.94B |
Last Dividend | $0.324 ( 2023-06-02 ) |
Next Dividend | $0 ( N/A ) |
P/E | 14.96 |
ATR14 | $0 (0.00%) |
Ipsen S.A. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ipsen S.A. Finanzas
Annual | 2023 |
Ingresos: | $3.13B |
Beneficio Bruto: | $2.35B (75.10 %) |
EPS: | $7.79 |
FY | 2023 |
Ingresos: | $3.13B |
Beneficio Bruto: | $2.35B (75.10 %) |
EPS: | $7.79 |
FY | 2022 |
Ingresos: | $3.16B |
Beneficio Bruto: | $2.63B (83.28 %) |
EPS: | $1.970 |
FY | 2021 |
Ingresos: | $3.00B |
Beneficio Bruto: | $2.46B (82.06 %) |
EPS: | $1.948 |
Financial Reports:
No articles found.
Ipsen S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.324 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.262 | 2013-06-11 |
Last Dividend | $0.324 | 2023-06-02 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-27 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $3.05 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.56 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.15 | |
Div. Directional Score | 9.82 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SGPYY | Ex Dividend Knight | 2023-06-01 | Semi-Annually | 0 | 0.00% | |
GMVHY | Ex Dividend Junior | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
AILLO | Ex Dividend Knight | 2023-07-14 | Semi-Annually | 0 | 0.00% | |
NACB | Ex Dividend Junior | 2023-08-15 | Quarterly | 0 | 0.00% | |
CPKF | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
SZLMY | Ex Dividend Junior | 2023-05-03 | Annually | 0 | 0.00% | |
HONT | Ex Dividend Junior | 2023-08-14 | Quarterly | 0 | 0.00% | |
AVHNY | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
OVCHY | Ex Dividend Junior | 2023-08-15 | Annually | 0 | 0.00% | |
DURYY | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.102 | 1.200 | 6.60 | 7.92 | [0 - 0.3] |
returnOnEquityTTM | 0.178 | 1.500 | 9.13 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.155 | -1.000 | 8.45 | -8.45 | [0 - 1] |
currentRatioTTM | 1.167 | 0.800 | 9.17 | 7.33 | [1 - 3] |
quickRatioTTM | 0.864 | 0.800 | 9.63 | 7.70 | [0.8 - 2.5] |
cashRatioTTM | 0.325 | 1.500 | 9.31 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0626 | -1.500 | 8.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 37.44 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.99 | 2.00 | 6.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.103 | -1.500 | 9.59 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.817 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.314 | 1.000 | 5.73 | 5.73 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.13 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.495 | 0.800 | -0.0358 | -0.0286 | [0.5 - 2] |
Total Score | 13.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 3.63 | 1.000 | 9.73 | 0 | [1 - 100] |
returnOnEquityTTM | 0.178 | 2.50 | 9.44 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.99 | 2.00 | 7.34 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.145 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.20 | 2.00 | 6.60 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.155 | 1.500 | 8.45 | -8.45 | [0 - 1] |
pegRatioTTM | 0.0973 | 1.500 | -2.68 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.270 | 1.000 | 5.76 | 0 | [0.1 - 0.5] |
Total Score | 6.15 |
Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico